AR059743A1 - Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol - Google Patents

Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol

Info

Publication number
AR059743A1
AR059743A1 ARP070100904A ARP070100904A AR059743A1 AR 059743 A1 AR059743 A1 AR 059743A1 AR P070100904 A ARP070100904 A AR P070100904A AR P070100904 A ARP070100904 A AR P070100904A AR 059743 A1 AR059743 A1 AR 059743A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulation
weight
component
fluor
hydroxyphenyl
Prior art date
Application number
ARP070100904A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059743A1 publication Critical patent/AR059743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente está dirigida a formulaciones farmacéuticas de una forma cristalina de monohidrato de un modulador de un receptor estrogénico, y composiciones farmacéuticas y procedimientos para la preparacion de éstas. Reivindicacion 2: Una formulacion farmacéutica líquida o semi-solida que comprende: (a) un primer componente portador que comprende desde aproximadamente 10% hasta aproximadamente 99,99% en peso de dicha formulacion farmacéutica; (b) un segundo componente portador opcional que comprende hasta aproximadamente 70% en peso de dicha formulacion farmacéutica; (c) un componente emulsionante/solubilizante que comprende desde aproximadamente 0,01% hasta aproximadamente 30% en peso de dicha formulacion farmacéutica; (d) un componente anti-cristalizacion/solubilizacion opcional que comprende desde aproximadamente 0,01% hasta aproximadamente 30% en peso de dicha formulacion farmacéutica; y (e) un agente farmacologico activo que comprende desde aproximadamente 0,01% hasta aproximadamente 80% de dicha formulacion farmacéutica, donde dicho agente farmacologico activo comprende la forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol. Reivindicacion 40: Una formulacion farmacéutica que comprende: (a) un primer componente diluyente/rellenador que comprende desde aproximadamente 30% hasta aproximadamente 95% en peso de dicha formulacion; (b) un segundo componente diluyente/rellenador opcional que comprende hasta aproximadamente 40% en peso de dicha formulacion farmacéutica; (c) un componente desintegrante que comprende desde aproximadamente 0,01% hasta aproximadamente 30% en peso de dicha formulacion farmacéutica; (d) un componente aglutinante que comprende desde aproximadamente 0,01% hasta aproximadamente 20% en peso de dicha formulacion farmacéutica; (e) un componente agente humectante que comprende desde aproximadamente 0,01% hasta aproximadamente 20% en peso de dicha formulacion farmacéutica; (f) un componente lubricante opcional que comprende desde aproximadamente 0,01% hasta aproximadamente 10% en peso de dicha formulacion farmacéutica; y (g) un agente farmacologico activo que comprende desde aproximadamente 0,01% hasta aproximadamente 80% en peso de dicha formulacion farmacéutica, donde dicho agente farmacologico activo comprende la forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol.
ARP070100904A 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol AR059743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77989206P 2006-03-06 2006-03-06

Publications (1)

Publication Number Publication Date
AR059743A1 true AR059743A1 (es) 2008-04-23

Family

ID=38475772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100904A AR059743A1 (es) 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol

Country Status (6)

Country Link
US (1) US20070207202A1 (es)
AR (1) AR059743A1 (es)
PA (1) PA8717801A1 (es)
PE (1) PE20080116A1 (es)
TW (1) TW200800178A (es)
WO (1) WO2007103877A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146630A1 (en) * 2006-11-21 2008-06-19 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080176914A1 (en) * 2006-11-21 2008-07-24 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080139633A1 (en) * 2006-11-21 2008-06-12 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080132554A1 (en) * 2006-11-21 2008-06-05 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437599C2 (de) * 1984-10-13 1987-04-16 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende Weichgelatinekapseln
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20060121111A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
GT200500349A (es) * 2004-12-02 2006-07-03 Formulaciones de benzoxazoles substituidos
AU2005312031A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
CA2600339A1 (en) * 2005-03-08 2006-09-14 Wyeth Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and their use as estrogen receptor modulators
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands

Also Published As

Publication number Publication date
WO2007103877A3 (en) 2007-11-22
PA8717801A1 (es) 2009-04-23
PE20080116A1 (es) 2008-02-25
TW200800178A (en) 2008-01-01
US20070207202A1 (en) 2007-09-06
WO2007103877A2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
AR059743A1 (es) Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol
DOP2007000024A (es) Composiciones herbicidas concentradas y estables
PE20080117A1 (es) Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
AR069301A1 (es) Modificadores de asfalto para aplicaciones de mezcla tibia que incluyen promotor de la adhesion
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
ECSP056095A (es) Métodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero
WO2010041141A3 (en) Oil-based foamable carriers and formulations
AR059741A1 (es) Formulaciones farmaceuticas liquidas y semisolidas y procedimientos
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CL2012000824A1 (es) Anticuerpo que se une especificamente al epitopo que se une especificamente a un receptor epha2; conjugado de dicho anticuerpo que comprende un agente citotoxico derivado de un compuesto maitansinoide; metodo para preparar dicho conjugado; composicion farmaceutica.
PT2038290E (pt) Moduladores de receptor do tipo toll 7
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
MX2009003735A (es) Composicion en deposito inyectable y su procedimiento de preparacion.
ECSP088239A (es) Composición de liberación de fármaco sostenida
MX355683B (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
UY30462A1 (es) Composicion farmacéuticas que contiene un acido tetrahidrofolico.
CU20120080A7 (es) Formulaciones de anticuerpo
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
AR081036A1 (es) Formulaciones farmaceuticas para tratar enfermedades relacionadas con el transportador de glucosa dependiente de sodio
AR084978A1 (es) Metodo y composicion para suministrar ingrediente activo al aire y su uso
GT200500358A (es) Compuestos organicos
CL2008001775A1 (es) Compuestos derivados de 2-amino-7-alquinil-[1,8]naftiridona, inhibidores de vegfr-3; composición farmacéutica; combinación farmacéutica; procedimiento de preparación; compuesto intermediario; y uso en el tratamiento del cáncer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal